过刊浏览

胰高血糖素样肽1：阿尔茨海默病治疗新策略

王晓晖, 杨威, 祁金顺^*

山西医科大学生理学系，细胞生理学省部共建教育部重点实验室，太原 030001

摘要

2 型糖尿病(type 2 diabetes mellitus, T2DM)与阿尔茨海默病(Alzheimer’s disease, AD)的病理生理过程具有密切的相关性。人们正在逐步深入研究治疗T2DM的最新药物——胰高血糖素样肽1 (glucagon-like peptide 1, GLP-1)的神经保护作用，并大胆地提出了利用GLP-1 治疗AD 的设想。本文对T2DM 与AD 的发病相关性、GLP-1 的合成与分泌、GLP-1 受体的中枢分布及其生理效应，特别是GLP-1 与AD 治疗策略相关的研究进展作一综述。

关键词： 胰高血糖素样肽1; 神经保护; 阿尔茨海默病; 2 型糖尿病; β - 淀粉样蛋白

分类号：R338.64

[Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer’s disease.] [Ariticle in Chinese]

WANG Xiao-Hui, YANG Wei, QI Jin-Shun^*

Department of Physiology, Key Laboratory for Cellular Physiology of Ministry of Education, Shanxi Medical University, Taiyuan 030001, China

Abstract

There is a close correlation between type 2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD) in the course ofpathophysiological processes. The neuroprotective action of glucagon-like peptide 1 (GLP-1), a latest drug for clinical treatment ofT2DM, is being more deeply investigated at present, and a novel therapeutic strategy for AD with GLP-1 has been proposed boldly.This review mainly discussed the correlation of pathogenesis between T2DM and AD, the synthesis and secretion of GLP-1, thedistribution and physiological effects of GLP-1 receptor in the brain, and the progresses on the study of GLP-1 in the treatment of AD.

Key words: glucagon-like peptide 1; neuroprotection; Alzheimer's disease; type 2 diabetes mellitus; amyloid-β peptide

收稿日期：2010-07-14　　录用日期：2010-08-03

通讯作者：祁金顺　　E-mail: jinshunqi2006@yahoo.com

引用本文：

王晓晖, 杨威, 祁金顺. 胰高血糖素样肽1：阿尔茨海默病治疗新策略[J]. 生理学报 2010; 62 (5): 398-406.

WANG Xiao-Hui, YANG Wei, QI Jin-Shun. [Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer’s disease.] [Ariticle in Chinese] . Acta Physiol Sin 2010; 62 (5): 398-406 (in Chinese with English abstract).